Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?

Smart Beta ETF report for DVYE

Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?

Smart Beta ETF report for DVYE

Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?

Smart Beta ETF report for DVYE

Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aduro Biotech's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?

Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?

Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Aduro Biotech (ADRO) Reports Q1 Loss, Tops Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound?

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shuvra Shankar Dey headshot

4 Cheap Stocks to Buy on Signs of Coronavirus Slowdown

The highly oversold market offers some ultra-cheap stocks with stellar prospects as the coronavirus pandemic shows signs of slowing down.

Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know

Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.

Has Aduro Biotech (ADRO) Outpaced Other Medical Stocks This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

Shuvra Shankar Dey headshot

4 Ultra-Cheap Stocks to Abate Coronavirus-Led Investment Agony

We have picked stocks that trade under $10 with stellar bottom-line projections, positive estimate revisions and impressive share-price rally, indicating momentum in the mid-term.

Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know

Aduro Biotech (ADRO) closed at $2.53 in the latest trading session, marking a +1.2% move from the prior day.

Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4

Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.

Aduro Biotech (ADRO) Reports Q4 Loss, Lags Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -14.29% and -26.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Aduro Biotech (ADRO) Stock Moves -0.6%: What You Should Know

Aduro Biotech (ADRO) closed the most recent trading day at $3.33, moving -0.6% from the previous trading session.

AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

Sanghamitra Saha headshot

5 Reasons to Buy These Small-Cap Stocks Now

After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.